These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 32125928)

  • 1. Likelihood of Nonspecific Activity of Gapmer Antisense Oligonucleotides Is Associated with Relative Hybridization Free Energy.
    Watt AT; Swayze G; Swayze EE; Freier SM
    Nucleic Acid Ther; 2020 Aug; 30(4):215-228. PubMed ID: 32125928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of gapmer antisense oligonucleotide with deoxyribonucleic guanidine (DNG) modifications.
    Kojima N; Shrestha AR; Akisawa T; Piao H; Kizawa H; Ohmiya Y; Kurita R
    Nucleosides Nucleotides Nucleic Acids; 2020; 39(1-3):258-269. PubMed ID: 31556356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the effect of 2'-O-methyl, fluoro hexitol, bicyclo and Morpholino nucleic acid modifications on potency of GalNAc conjugated antisense oligonucleotides in mice.
    Prakash TP; Yu J; Kinberger GA; Low A; Jackson M; Rigo F; Swayze EE; Seth PP
    Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3774-3779. PubMed ID: 30342955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding the effect of controlling phosphorothioate chirality in the DNA gap on the potency and safety of gapmer antisense oligonucleotides.
    Østergaard ME; De Hoyos CL; Wan WB; Shen W; Low A; Berdeja A; Vasquez G; Murray S; Migawa MT; Liang XH; Swayze EE; Crooke ST; Seth PP
    Nucleic Acids Res; 2020 Feb; 48(4):1691-1700. PubMed ID: 31980820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the Knockdown Activity of MALAT1 ENA Gapmers In Vitro.
    Iwashita S; Shoji T; Koizumi M
    Methods Mol Biol; 2020; 2176():155-161. PubMed ID: 32865789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In silico and in vitro evaluation of exonic and intronic off-target effects form a critical element of therapeutic ASO gapmer optimization.
    Kamola PJ; Kitson JD; Turner G; Maratou K; Eriksson S; Panjwani A; Warnock LC; Douillard Guilloux GA; Moores K; Koppe EL; Wixted WE; Wilson PA; Gooderham NJ; Gant TW; Clark KL; Hughes SA; Edbrooke MR; Parry JD
    Nucleic Acids Res; 2015 Oct; 43(18):8638-50. PubMed ID: 26338776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts.
    Burel SA; Hart CE; Cauntay P; Hsiao J; Machemer T; Katz M; Watt A; Bui HH; Younis H; Sabripour M; Freier SM; Hung G; Dan A; Prakash TP; Seth PP; Swayze EE; Bennett CF; Crooke ST; Henry SP
    Nucleic Acids Res; 2016 Mar; 44(5):2093-109. PubMed ID: 26553810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute hepatotoxicity of 2' fluoro-modified 5-10-5 gapmer phosphorothioate oligonucleotides in mice correlates with intracellular protein binding and the loss of DBHS proteins.
    Shen W; De Hoyos CL; Sun H; Vickers TA; Liang XH; Crooke ST
    Nucleic Acids Res; 2018 Mar; 46(5):2204-2217. PubMed ID: 29390093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of 2'-O-[2-[2-(N,N-dimethylamino)ethoxy]ethyl] modification on activity of gapmer antisense oligonucleotides containing 2',4'-constrained 2'-O-ethyl nucleic acid.
    Pandey SK; Nowak A; Perkins J; Ferng A; Prakash TP
    Bioorg Med Chem Lett; 2015 Apr; 25(8):1688-1691. PubMed ID: 25804718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of off-target effects of gapmer antisense oligonucleotides using human cells.
    Yoshida T; Naito Y; Yasuhara H; Sasaki K; Kawaji H; Kawai J; Naito M; Okuda H; Obika S; Inoue T
    Genes Cells; 2019 Dec; 24(12):827-835. PubMed ID: 31637814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Combination of Mesyl-Phosphoramidate Inter-Nucleotide Linkages and 2'-
    Zhang L; Liang XH; De Hoyos CL; Migawa M; Nichols JG; Freestone G; Tian J; Seth PP; Crooke ST
    Nucleic Acid Ther; 2022 Oct; 32(5):401-411. PubMed ID: 35861704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of Off-Target Effects of Gapmer Antisense Oligonucleotides by Oligonucleotide Extension.
    Yasuhara H; Yoshida T; Sasaki K; Obika S; Inoue T
    Mol Diagn Ther; 2022 Jan; 26(1):117-127. PubMed ID: 34994962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of combinations of gapmer antisense oligonucleotides on the target reduction.
    Yanagidaira M; Yoshioka K; Nagata T; Nakao S; Miyata K; Yokota T
    Mol Biol Rep; 2023 Apr; 50(4):3539-3546. PubMed ID: 36787053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hybridization-mediated off-target effects of splice-switching antisense oligonucleotides.
    Scharner J; Ma WK; Zhang Q; Lin KT; Rigo F; Bennett CF; Krainer AR
    Nucleic Acids Res; 2020 Jan; 48(2):802-816. PubMed ID: 31802121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-sensitivity quantification of antisense oligonucleotides for pharmacokinetic characterization.
    Mahajan S; Zhao H; Kovacina K; Lachacz E; Hoxha S; Chan J; Liang M
    Bioanalysis; 2022 May; 14(9):603-613. PubMed ID: 35578971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index.
    Shen W; De Hoyos CL; Migawa MT; Vickers TA; Sun H; Low A; Bell TA; Rahdar M; Mukhopadhyay S; Hart CE; Bell M; Riney S; Murray SF; Greenlee S; Crooke RM; Liang XH; Seth PP; Crooke ST
    Nat Biotechnol; 2019 Jun; 37(6):640-650. PubMed ID: 31036929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hsp90 protein interacts with phosphorothioate oligonucleotides containing hydrophobic 2'-modifications and enhances antisense activity.
    Liang XH; Shen W; Sun H; Kinberger GA; Prakash TP; Nichols JG; Crooke ST
    Nucleic Acids Res; 2016 May; 44(8):3892-907. PubMed ID: 26945041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimated number of off-target candidate sites for antisense oligonucleotides in human mRNA sequences.
    Yoshida T; Naito Y; Sasaki K; Uchida E; Sato Y; Naito M; Kawanishi T; Obika S; Inoue T
    Genes Cells; 2018 Jun; 23(6):448-455. PubMed ID: 29667281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antisense locked nucleic acids efficiently suppress BCR/ABL and induce cell growth decline and apoptosis in leukemic cells.
    Rapozzi V; Cogoi S; Xodo LE
    Mol Cancer Ther; 2006 Jul; 5(7):1683-92. PubMed ID: 16891454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bolaamphiphile-based nanocomplex delivery of phosphorothioate gapmer antisense oligonucleotides as a treatment for Clostridium difficile.
    Hegarty JP; Krzeminski J; Sharma AK; Guzman-Villanueva D; Weissig V; Stewart DB
    Int J Nanomedicine; 2016; 11():3607-19. PubMed ID: 27536102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.